Insulet Co. (NASDAQ:PODD) Shares Sold by Korea Investment CORP

Korea Investment CORP lowered its stake in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 11.1% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 37,671 shares of the medical instruments supplier's stock after selling 4,700 shares during the period. Korea Investment CORP owned approximately 0.05% of Insulet worth $9,835,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in PODD. SBI Securities Co. Ltd. purchased a new position in shares of Insulet in the fourth quarter valued at approximately $36,000. SRS Capital Advisors Inc. boosted its position in Insulet by 43.1% in the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock valued at $49,000 after buying an additional 56 shares during the period. Friedenthal Financial acquired a new position in shares of Insulet in the fourth quarter worth $57,000. TD Private Client Wealth LLC increased its position in shares of Insulet by 32.6% during the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier's stock worth $53,000 after acquiring an additional 56 shares during the period. Finally, Assetmark Inc. increased its position in shares of Insulet by 1,447.1% during the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock worth $69,000 after acquiring an additional 246 shares during the period.

Wall Street Analyst Weigh In

PODD has been the subject of a number of analyst reports. Raymond James reissued an "outperform" rating and set a $328.00 price objective (up from $294.00) on shares of Insulet in a research report on Friday, February 21st. Piper Sandler increased their price objective on shares of Insulet from $285.00 to $310.00 and gave the company an "overweight" rating in a research report on Friday, February 21st. JPMorgan Chase & Co. lifted their price objective on shares of Insulet from $280.00 to $330.00 and gave the stock an "overweight" rating in a research report on Thursday, December 12th. StockNews.com lowered Insulet from a "buy" rating to a "hold" rating in a report on Tuesday, March 4th. Finally, TD Cowen lifted their price target on Insulet from $264.00 to $324.00 and gave the stock a "buy" rating in a report on Friday, January 3rd. Four research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat, Insulet currently has a consensus rating of "Moderate Buy" and a consensus target price of $292.06.

Remove Ads

Insulet Stock Performance

Shares of NASDAQ:PODD traded down $11.54 during trading on Friday, reaching $245.26. The company had a trading volume of 1,337,197 shares, compared to its average volume of 713,775. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $289.46. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The stock's fifty day moving average price is $269.86 and its 200 day moving average price is $259.70. The firm has a market capitalization of $17.22 billion, a price-to-earnings ratio of 42.36, a price-to-earnings-growth ratio of 3.62 and a beta of 1.30.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.15. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The company had revenue of $597.50 million for the quarter, compared to analysts' expectations of $582.02 million. As a group, equities research analysts predict that Insulet Co. will post 3.92 EPS for the current year.

Insider Activity at Insulet

In other Insulet news, Director Wayne A.I. Frederick sold 1,825 shares of the firm's stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the completion of the sale, the director now owns 3,231 shares of the company's stock, valued at approximately $888,525. This trade represents a 36.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the transaction, the executive vice president now owns 11,383 shares of the company's stock, valued at $3,187,240. This represents a 52.13 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is owned by insiders.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.